Sabine Mueller

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma
    Sabine Mueller
    Department of Neurology, University of California, San Francisco, 675 Nelson Ring, Sandler Neuroscience Center, UCSF, San Francisco, CA 94148, USA
    Anticancer Res 33:755-62. 2013
  2. ncbi Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms
    Sabine Mueller
    Department of Neurology, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143 0106, USA
    Cancer Lett 306:223-9. 2011
  3. ncbi Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study
    Sabine Mueller
    Department of Neurology, University of San Francisco, 350 Parnassus Ave, Suite 609, San Francisco, CA 94117, USA
    J Neurooncol 101:267-77. 2011
  4. ncbi Pediatric brain tumors: current treatment strategies and future therapeutic approaches
    Sabine Mueller
    Department of Neurology, Division of Child Neurology, University of San Francisco, San Francisco, California, USA
    Neurotherapeutics 6:570-86. 2009
  5. ncbi High-grade gliomas in children
    Tene A Cage
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143 0112, USA
    Neurosurg Clin N Am 23:515-23. 2012
  6. ncbi Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
    Gautam Prasad
    Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA
    Neuro Oncol 13:384-92. 2011
  7. ncbi PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome
    Sabine Mueller
    Department of Pediatrics, University of California, San Francisco, CA, USA
    Neuro Oncol 14:1146-52. 2012
  8. ncbi Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems
    Swati S More
    Departments of Bioengineering and Therapeutic Sciences, UCSF School of Medicine and UCSF Benioff Children s Hospital, San Francisco, California 94158, USA
    Clin Cancer Res 17:2339-49. 2011
  9. ncbi The superiority of conservative resection and adjuvant radiation for craniopharyngiomas
    Adam Schoenfeld
    Department of Radiation Oncology, University of California, San Francisco UCSF, San Francisco, CA 94143 1708, USA
    J Neurooncol 108:133-9. 2012
  10. ncbi Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment
    Rintaro Hashizume
    Department of Neurological Surgery, Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143 0520, USA
    J Neurooncol 110:305-13. 2012

Detail Information

Publications11

  1. ncbi Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma
    Sabine Mueller
    Department of Neurology, University of California, San Francisco, 675 Nelson Ring, Sandler Neuroscience Center, UCSF, San Francisco, CA 94148, USA
    Anticancer Res 33:755-62. 2013
    ..To assess poly (ADP-ribose) polymerase (PARP) inhibitor MK-4827 together with radiation for the treatment of neuroblastoma...
  2. ncbi Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms
    Sabine Mueller
    Department of Neurology, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143 0106, USA
    Cancer Lett 306:223-9. 2011
    ..DNA repair enzyme Ku-86 was reduced in several neuroblastoma cells treated with vorinostat. Thus, vorinostat potentiates anti-neoplastic effects of radiation in neuroblastoma possibly due to down-regulation of DNA repair enzyme Ku-86...
  3. ncbi Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study
    Sabine Mueller
    Department of Neurology, University of San Francisco, 350 Parnassus Ave, Suite 609, San Francisco, CA 94117, USA
    J Neurooncol 101:267-77. 2011
    ..55; PFS: P = 0.35) or imaging changes on day 43 MRI (P = 0.88). Catheter positioning scores and overall catheter placement scores were not associated with clinical outcome in this large prospective trial...
  4. ncbi Pediatric brain tumors: current treatment strategies and future therapeutic approaches
    Sabine Mueller
    Department of Neurology, Division of Child Neurology, University of San Francisco, San Francisco, California, USA
    Neurotherapeutics 6:570-86. 2009
    ..This article will outline current and future therapeutic strategies for the most common pediatric CNS tumors, including primitive neuroectodermal tumors such as medulloblastoma, as well as astrocytomas and ependymomas...
  5. ncbi High-grade gliomas in children
    Tene A Cage
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143 0112, USA
    Neurosurg Clin N Am 23:515-23. 2012
    ..This article reviews clinical, diagnostic, and pathologic features of HGG and current treatments and potential future therapies specific to pediatric patients with HGGs...
  6. ncbi Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
    Gautam Prasad
    Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA
    Neuro Oncol 13:384-92. 2011
    ..05) with a trend toward improvement in median survival (logrank p = 0.09) compared with TMZ alone. XL765 shows activity as monotherapy and in combination with conventional therapeutics in a range of genetically diverse GBM xenografts...
  7. ncbi PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome
    Sabine Mueller
    Department of Pediatrics, University of California, San Francisco, CA, USA
    Neuro Oncol 14:1146-52. 2012
    ..0475). Tumors with no PTEN expression had a higher MIB labeling index (P= .007). The majority of pediatric gliomas show activation of the PI3K/Akt/mTOR pathway, with methylation of the PTEN promoter occurring commonly in these tumors...
  8. ncbi Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems
    Swati S More
    Departments of Bioengineering and Therapeutic Sciences, UCSF School of Medicine and UCSF Benioff Children s Hospital, San Francisco, California 94158, USA
    Clin Cancer Res 17:2339-49. 2011
    ....
  9. ncbi The superiority of conservative resection and adjuvant radiation for craniopharyngiomas
    Adam Schoenfeld
    Department of Radiation Oncology, University of California, San Francisco UCSF, San Francisco, CA 94143 1708, USA
    J Neurooncol 108:133-9. 2012
    ..014). In conclusion, for patients with craniopharyngioma, STR + RT may provide superior clinical outcome, achieving better disease control than STR and limiting side effects associated with aggressive surgical resection...
  10. ncbi Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment
    Rintaro Hashizume
    Department of Neurological Surgery, Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143 0520, USA
    J Neurooncol 110:305-13. 2012
    ..The hTERT modified cells are tumorigenic in athymic rodents, and produce brainstem tumors that recapitulate the infiltrative growth of brainstem gliomas in patients...
  11. ncbi Neuroblastoma: biology and staging
    Sabine Mueller
    Department of Pediatric Hematology Oncology, University of California, San Francisco School of Medicine, M647, 505 Parnassus Avenue, San Francisco, CA 94143, USA
    Curr Oncol Rep 11:431-8. 2009
    ..This review discusses the biology of these tumors, current and new risk classification, and staging recommendations, with a brief outline of preferred treatment strategies...